JPMorgan Chase & Co.'s Chief Executive Jamie Dimon told analysts on Wednesday he plans to stay in the job "for a few more ...

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/98.DhP-XEBZ.js ...

Global brokerage JP Morgan believes that both Swiggy and Zomato are available at attractive prices for taking positions in ...

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

Illumina’s Q4 revenue in 2024 was up 1% from the same period in 2023, totalling $1.1bn. Despite the positive end to the year, ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

JPMorgan’s net income soared 50% to more than $14 billion in the fourth quarter as the bank’s profit and revenue easily beat ...

While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...

Bruce Cozadd, the retiring CEO of Jazz Pharmaceuticals, has outlined a developing oncology pipeline at the company. Speaking ...

In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...

At the JP Morgan Healthcare Conference 2025, Charles River CEO blamed low client spending, loss of a contract and other reasons for lower 2025 projections.